Antigen Discovery Scores $1.8M from NIAID to Develop Chlamydia Vaccine

Firm will use the money to identify a subset of recombinant antigens that induce strong protection from candidate antigens found in the phase 1 STTR program.

Icagen Lands One-Year, $5M Extension to Pfizer Collaboration for Pain Therapies

Agreement covers development of compounds that modify three specific sodium ion channels as treatments for pain and related disorders.

AstraZeneca Pays Nektar $125M to Take On Two Opioid Therapy Programs

Drug to treat constipation combines small molecule polymer conjugate technology platform with naloxol, a derivative of the opioid-antagonist, naloxone.

India-Based CRO SIRO ClinPharm Allies with Regulatory Consultancy Firm CamReg

India-based CRO SIRO Clinpharm formed a strategic alliance with Cambridge Regulatory Services, a full-service regulatory consultancy for the pharmaceutical industry. The companies claim their...

Ambrx and Wyeth Sign Multitarget Alliance to Develop Protein Drugs

Deal will exploit Ambrx’ biologics optimization technologies, ReCODE™ and EuCODE™. They enable site-selective substitution of novel amino acids.

Wellcome Trust and Merck Set Up JV to Focus on Vaccines...

India-based Hilleman Laboratories is considering developing vaccines that do not require refrigeration and a vaccine against Group A streptococci.

PerkinElmer Buys GE’s Catalog Radiochemicals, SPA Reagents, and Cytostar-T Plate Assets

Deal pad GPCR and kinase research product lines as well as offerings for detection and screening of new drugs, radiolabeling, bead-based assays, HTS, and reagents.

PPD Opens Lab in Singapore to Support Demand in Southeast Asia

CRO continues making inroads into Asia as well as Central and Eastern Europe. It previously acquired AbCRO and Magen, established an office in Tokyo.

FDA Okays Vaccines for 2009 H1N1 Influenza Virus

CSL, MedImmune, Novartis, and Sanofi Pasteur will begin supply within the next four weeks. Sanofi's vaccine is indicated for children as young as six months.

Value of Elan’s Deal with J&J Drops by 7.6%

Breach of contract with Biogen Idec related to Tysabri forced Elan to eliminate certain financing terms.